The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
The Danish biotech company confirmed the global study will begin in the second half of 2026
Health innovations are viewed more positively than food and agricultural technologies
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
New home-use glucometer delivers results in under 10 seconds with simplified testing, large memory storage, and user-friendly design
The submission is backed by positive results from the Phase 3 AFFIRM study
nSEPIA aims to bring structure to an area long dominated by subjectivity
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
Subscribe To Our Newsletter & Stay Updated
